The government has approved the conduct of two clinical trials in Andhra Medical College/King George Hospital in Visakhapatnam. A communiqué from the Directorate of Medical Education, Vijayawada, was received in this regard by the hospital. The trail may begin in another two weeks’ time.
The trials for which permission was granted are Phase II clinical trial of CRO Navitas Life Sciences in the acute treatment of moderate to severe Covid-19 cases. The study has the support of DRDO. Dr Y Gyana Sundar Raju, Prof of General Medicine, has been appointed as the principal investigator for the study. Another one is, Phase 2/3 single blind randomised control study to determine the safety and immunogenicity of the Coronavirus vaccine (COVISHIELD) of Serum Institute of India.
This study has the support of ICMR. Dr B Devi Madhavi, Prof of Community Medicine, will be the principal investigator for the vaccine trial. A team of experts from various departments are co-investigators for the studies. The Collector and District Magistrate has congratulated the institute and wished all the best. Earlier, KGH was chosen by ICMR for the Covid vaccine, Covaxin jointly being developed by ICMR and Bharat Biotech International Limited (BBIL).
However, KGH is waiting for the approval of the same, according to the Andhra Medical College principal Dr. PV Sudhakar. KGH was the only institute from Andhra Pradesh to make it to the list of 12 medical institutes chosen by the ICMR as the clinical trial sites for the vaccine (Covaxin). Apart from IMS and SUM Hospital in Bhubaneswar, the other institutes selected for the clinical trial are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.
Mr. V Vinay Chand, District Collector, and Magistrate congratulated the institute and wished all the best.
CLICK HERE !! To be found on google search engine